title: Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.
abstract: Restenosis is one of the main complications in patients undergoing coronary or peripheral revascularization procedures and is the leading cause for their long-term failures. Cilostazol is the only pharmacotherapy that showed an adequate efficacy for preventing restenosis in randomized, controlled studies after coronary or peripheral revascularization procedures. The present review sums up the main clinical evidence supporting the use of cilostazol after revascularization interventions, focusing on all its benefits, warnings, and administration schedules.
authors.affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. Electronic address: dedonato@unisi.it.
authors.forename: Gianmarco
authors.initials: G
authors.lastname: de Donato
authors.affiliation: Clinica Casa di Cura Giovanni XXIII, Monastier di Treviso, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Setacci
authors.affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
authors.forename: Mariagnese
authors.initials: M
authors.lastname: Mele
authors.affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Giannace
authors.affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Galzerano
authors.affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Setacci
mesh_terms: D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077407:Cilostazol; D003324:Coronary Artery Disease / Q000503:physiopathology / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D057510:Endovascular Procedures / Q000009:adverse effects*; D006801:Humans; D058729:Peripheral Arterial Disease / Q000503:physiopathology / Q000628:therapy*; D012008:Recurrence; D012307:Risk Factors; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D013777:Tetrazoles; D000077407:Cilostazol